Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Innoviva Inc (NQ: INVA )

13.99 +0.14 (+1.01%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 494,735
Open 13.97
Bid (Size) 12.00 (1)
Ask (Size) 13.98 (3)
Prev. Close 13.85
Today's Range 13.69 - 14.00
52wk Range 10.64 - 14.08
Shares Outstanding 65,504,384
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea
From Innoviva Specialty Therapeutics
Via Business Wire

Performance

YTD
+5.43%
+5.43%
1 Month
+12.64%
+12.64%
3 Month
+9.13%
+9.13%
6 Month
+6.23%
+6.23%
1 Year
+6.15%
+6.15%

More News

Read More
A Look Into Healthcare Sector Value Stocks
Via Benzinga
Innoviva to Participate in the Cantor Global Healthcare Conference
From Innoviva, Inc.
Via Business Wire
A Look Into Healthcare Sector Value Stocks
Via Benzinga
5 Value Stocks In The Healthcare Sector
Via Benzinga
FDA's AdComm Panel Favors Innoviva's Drug For Multidrug-Resistant Bacterial Infections
Via Benzinga
XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults
From Innoviva, Inc.
Via Business Wire
Innoviva Appoints Stephen Basso as Chief Financial Officer
From Innoviva, Inc.
Via Business Wire
Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Overview Of Value Stocks In The Healthcare Sector
Via Benzinga
What 4 Analyst Ratings Have To Say About Innoviva
Via Benzinga
Why These 7 Stocks Are the Best Ways to Play Biotech Right Now
Via InvestorPlace
Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference
From Innoviva, Inc.
Via Business Wire
AstraZeneca-Spin Off Entasis Secures FDA Approval For First Pathogen-Targeted Therapy Addressing Acinetobacter
Via Benzinga
Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use
From Innoviva, Inc.
Via Business Wire
Over $125M Bet On Occidental Petroleum? Check Out These 4 Stocks Insiders Are Buying
Via Benzinga
Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases
From Innoviva, Inc.
Via Business Wire
Innoviva Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Innoviva Announces Retirement of Board Chairman
From Innoviva, Inc.
Via Business Wire
Elon Musk Says US Intel Agencies Had Access To Twitter DMs, Alibaba's Ant IPO Might Actually See Light, Airbus Pushes Some 2024 Deliveries: Today's Top Stories
Via Benzinga
Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory Committee
From Innoviva, Inc.
Via Business Wire
Innoviva Stock Trading Halted Today
From Innoviva, Inc.
Via Business Wire
Innoviva Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigational Targeted Antibiotic
From Innoviva, Inc.
Via Business Wire
Innoviva Reports Fourth Quarter 2022 Financial Results and Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.